Table 1.
Results of the NMA of disease-modifying agents used in IPF patients [14]
| Outcome | Nintedanib (300 mg daily) versus placebo OR (95% CI) |
Pirfenidone (2403 mg daily) versus placebo OR (95% CI) |
|---|---|---|
| Overall survivala | 0.70 (0.45–1.09) | 0.69 (0.45–1.04) |
| Acute exacerbations | 0.56 (0.35–0.89) | 1.10 (0.43–2.85) |
| Loss of lung function | 0.54 (0.42–0.69) | 0.55 (0.41–0.72) |
| Serious cardiac events | 0.76 (0.45–1.27) | 1.26 (0.65–2.49) |
| Serious gastrointestinal events | 2.35 (1.05–5.88) | 0.60 (0.23–1.45) |
| Overall discontinuation | 1.42 (1.08–1.87) | 1.34 (1.34–1.73) |
CI confidence interval, NMA network meta-analysis, OR odds ratio
aThe OS OR values for nintedanib and pirfenidone vs placebo were used solely in sensitivity analysis scenarios. In the base-case analysis of this cost-effectiveness analysis, we assumed that the survival for patients on pirfenidone was the same as the survival for patients in the nintedanib arm